Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.64 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.61 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075799 | 0.90 | EGFR (0.70) | EGFRERBB4ERBB2MAP3K8ERBB3 | |
| SCHEMBL2951299 | 0.87 | EGFR (0.63) | EGFRERBB4ERBB2ERBB3 | |
| SCHEMBL13185141 | 0.86 | STK3 (0.55) | EGFRERBB4ERBB2MAP3K8 | |
| SCHEMBL20395121 | 0.86 | EGFR (0.79) | EGFRERBB4ERBB2ERBB3 | |
| SCHEMBL2201506 | 0.86 | EGFR (0.70) | EGFRERBB4ERBB2 | |
| Hydrochloric Acid SCHEMBL4962186 | 0.86 | EGFR (0.69) | EGFRERBB4ERBB2 | |
| SCHEMBL3593176 | 0.84 | EGFR (0.60) | EGFRERBB4ERBB2ERBB3 | |
| SCHEMBL3604713 | 0.83 | STK3 (0.70) | EGFRERBB4ERBB2MAP3K8ERBB3 | |
| SCHEMBL20395242 | 0.82 | EGFR (1.00) | EGFRERBB4ERBB2ERBB3 | |
| SCHEMBL233913 | 0.82 | EGFR (0.77) | EGFRERBB4ERBB2ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-09-06 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | EGFR, BRCA1, PTPRJ | EGFR 1/4885ERBB4 9/4885ERBB2 5/4885 |
| US-20120225872-A1 | METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES | ABL1, MAP3K7, MAP3K5 | EGFR 616/4885ERBB4 550/4885ERBB2 199/4885 |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | EGFR, BRCA1, PTPRJ | EGFR 1/4885ERBB4 9/4885ERBB2 5/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB4 407/4885ERBB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.